An increase in sedentary time from childhood is associated with worsening arterial stiffness, a surrogate for premature vascular damage, a new study shows. However, light physical activity could reduce the risk. The study ...
Mar 26, 2024
0
0
A newly developed compound is showing promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. The spread of schistosomiasis, a disease ...
Mar 25, 2024
0
0
Atherosclerosis is the major contributor to cardiovascular mortality worldwide. Diet-induced metabolic abnormalities including obesity, hyperglycemia, dyslipidemia, insulin resistance (IR), and non-alcoholic fatty liver disease ...
Mar 22, 2024
0
1
If you're in your 60s, 70s or even older, you might think your days of productively pumping iron are behind you.
Mar 22, 2024
0
2
Urinary tract infections (UTIs) caused by E. coli from aged care facilities show higher resistance to antibiotics compared to cases collected from hospitals and the wider community, find researchers from UNSW Sydney.
Mar 21, 2024
0
0
H. pylori is one of the most common disease-causing bacteria. More than half of the world's population have the bacteria in their body; and while in Canada overall prevalence of H. pylori is between 20% and 30%, some groups—including ...
Mar 20, 2024
0
0
Tuberculosis is the world's deadliest bacterial infection. It afflicted over 10 million people and took 1.3 million lives in 2022. These numbers are predicted to increase dramatically because of the spread of multidrug-resistant ...
Mar 20, 2024
0
0
Diabetes is a widespread metabolic disorder affecting over 500 million adults worldwide. The most common form is type-2 diabetes (T2D), characterized by peripheral insulin resistance.
Mar 19, 2024
0
13
A small, long-term study of almost 500 children in Massachusetts has found that regularly drinking sugary drinks and 100% fruit juices during childhood and adolescence may be linked to a higher risk of developing Type 2 diabetes ...
Mar 19, 2024
0
1
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed ...
Mar 19, 2024
0
3
